<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859455</url>
  </required_header>
  <id_info>
    <org_study_id>CLGT209X2105</org_study_id>
    <nct_id>NCT01859455</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Dose, Parallel Group Study to Assess the Safety, Tolerability, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LGT209 in Hypercholesterolemic Patients on Stable Doses of Atorvastatin or Simvastatin and in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications
      and in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of LGT209 following subcutaneous administration</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of atorvastatin in patients</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of simvastatin in patients</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of PCSK9</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>LDL Cholesterol</condition>
  <arm_group>
    <arm_group_label>Patient: LGT209 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: LGT209 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: LGT209 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGT209 50 mg</intervention_name>
    <description>Active experimental drug</description>
    <arm_group_label>Patient: LGT209 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGT209 300 mg</intervention_name>
    <description>Active experimental drug</description>
    <arm_group_label>Patient: LGT209 300 mg</arm_group_label>
    <arm_group_label>Healthy Volunteers: LGT209 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Patient: Placebo</arm_group_label>
    <arm_group_label>Healthy volunteers: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins (atorvastatin or simvastatin)</intervention_name>
    <description>Stable doses of atorvastatin or simvastatin</description>
    <arm_group_label>Patient: LGT209 50 mg</arm_group_label>
    <arm_group_label>Patient: LGT209 300 mg</arm_group_label>
    <arm_group_label>Patient: Placebo</arm_group_label>
    <other_name>Atorvastatin</other_name>
    <other_name>Simvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers: Male and female subjects 18 to 70 years of age, in general good
             health with fasting LDL-cholesterol &gt;90 mg/dL and fasting serum triglycerides &lt;400
             mg/dL

          -  Patients on statin therapy: Male and female patients 18 to 70 years of age receiving
             atorvastatin or simvastatin and with fasting LDL-cholesterol &gt;90 mg/dL and fasting
             serum triglycerides &lt;400 mg/dL

        Exclusion Criteria:

        Healthy volunteers:

          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes

          -  Women of child-bearing potential unless using highly effective methods of
             contraception

          -  Conditions which might impact the safety or biologic activity of the study drug

        Statin patients:

          -  Use of concomitant medications known to impact the safe use or efficacy of
             atorvastatin and simvastatin based on drug labels

          -  Women of childbearing potential unless using highly effective methods of contraception
             during dosing and for at least 100 days after study drug administration

          -  Conditions which might impact the safety or biologic activity of the study drug

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901-8144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia,</keyword>
  <keyword>LDL cholesterol lowering,</keyword>
  <keyword>proprotein convertase subtilisin/kexin type 9 (PCSK9),</keyword>
  <keyword>LGT209,</keyword>
  <keyword>drug safety,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

